Hairy Cell Leukemia (HCL): ‘Real World’ Outcome

HCL is an uncommon B cell lympho-proliferative disorder with high remission rates. There is paucity of data on the long-term outcome of HCL from India. We retrospectively collected data from individual case records of patients with HCL who were treated in Cancer Institute, Chennai from January 2001...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of hematology & blood transfusion 2020-04, Vol.36 (2), p.267-270
Main Authors: Joshi, Archit, Dhanushkodi, Manikandan, Ganesan, Prasanth, Radhakrishnan, Venkatraman, Kannan, Krishnarathinam, Mehra, Nikita, Kalaiyarasi, Jayachandran Perumal, Krupashankar, S., Sundersingh, Shirley, Ganesan, T. S., Sagar, T. G.
Format: Article
Language:English
Subjects:
Blood Transfusion Medicine
Cancer therapies
Clinical outcomes
Hematology
Human Genetics
Leukemia
Medicine
Medicine & Public Health
Oncology
Original
Original Article
Patients
Survivor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HCL is an uncommon B cell lympho-proliferative disorder with high remission rates. There is paucity of data on the long-term outcome of HCL from India. We retrospectively collected data from individual case records of patients with HCL who were treated in Cancer Institute, Chennai from January 2001 until January 2018. Sixteen patients were diagnosed with HCL and were treated with cladribine (81%), interferon (13%) and one patient received only best supportive care (6%). All the treated patients achieved complete response. More than half of the patients developed febrile neutropenia but there were no treatment related mortality. The 5-year DFS was 77% and 5-year OS was 80%. Relapse of disease was seen in 27%. HCL is a curable malignancy with high remission rates and survival comparable to patient treated in west.
ISSN:0971-4502
0974-0449
0974-0449
0971-4502
DOI:10.1007/s12288-019-01199-2